Advaxis, Inc.

Advaxis, Inc.

Advaxis, Inc.

Overview
Date Founded

2002

Headquarters

305 College Road East, Princeton, NJ, 8540, USA

Type of Company

Public

Employees (Worldwide)

58

Industries

Pharmaceuticals
IT Consulting & Services
Medical Support Services
Biotechnology

Company Description

Advaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. It has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy. The company was founded on June 5, 1987 and is headquartered in Princeton, NJ.

Contact Data
Trying to get in touch with decision makers at Advaxis, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

President & Chief Executive Officer

Executive Vice President & Chief Financial Officer

Executive Vice President & Chief Scientific Officer

Executive Vice President & Chief Medical Officer

Vice President, Business Development

Vice Chairman

Director of Research

Director

Board of Directors

Director, Head & Neck Cancer Research Division at Johns Hopkins University

Founder at VAL Health LLC

President & Chief Executive Officer at Advaxis, Inc.

Director at Advaxis, Inc.

Paths to Advaxis, Inc.
Potential Connections via
Relationship Science
You
Advaxis, Inc.
Owners & Shareholders
Details Hidden

Altium Capital Management LP is an American private company located in New York, NY, with subsidiaries in the United States, that provides investment advice.

Details Hidden

Empery Asset Management manages an event-driven, special situations fund that invests in small- to mid-sized growth companies. They make direct investments in US publicly-traded companies without respect to industry, although some of the companies are based in China.

Details Hidden

Altium Capital Management LP is an American private company located in New York, NY, with subsidiaries in the United States, that provides investment advice.

Recent Transactions
Details Hidden

Advaxis, Inc. issued USD Common Stock and Warrants

Details Hidden

Advaxis, Inc. issued USD Common Stock

Details Hidden

Advaxis, Inc. issued . USD Common Stock and Warrants

Transaction Advisors
Auditor

Advised onAdvaxis, Inc. issued Common Stock

Escrow Agent

Advised onAdvaxis, Inc. issued Common Stock

Investment Advisor

Advised onAdvaxis, Inc. raised money in a private placement transaction

Attorney

Advised onAdvaxis, Inc. issued USD Common Stock

Head of Investment Banking

Advised onAdvaxis, Inc. issued USD Common Stock

Legal Advisor

Advised onAdvaxis, Inc. issued Common Stock

Advisors & Consultants
Legal Advisor

Partner, San Diego at Cooley LLP

Legal Advisor

Shareholder at Greenberg Traurig LLP

Publicist

Professional at Jones Public Affairs, Inc.

Clients

Biocon, India's largest biotech company is focused on delivering affordable innovation. It is committed to reduce therapy costs of chronic diseases like diabetes, cancer and autoimmune diseases by leveraging India's cost advantage to deliver affordable healthcare solutions to patients, partners and healthcare systems across the globe. Biocon's key innovations include world's first Pichia based recombinant human Insulin, INSUGEN®, insulin analogue Glargine, BASALOG® and India's first indigenously produced monoclonal antibody BioMAb-EGFR®, for head & neck cancer. INSUPen® is a next generation affordable insulin delivery device introduced in India by Biocon. Its aspiration to become a US $ 1 billion company by FY 18 is fuelled by five powerful growth accelerators, Small Molecules, Biosimilars, Branded Formulations, Novel Molecules, and Research Services with a focus on emerging markets. Over the decades, Biocon has successfully evolved into an emerging global biopharma enterprise, serving its partners and customers in over 75 countries. As a fully integrated biopharma company it delivers innovative biopharmaceutical solutions, ranging from discovery to development and commercialization, leveraging the cutting edge science, cost-effective drug development capabilities and global scale manufacturing capacities, to move ideas to market. Leveraging India's globally competitive cost base and exceptional scientific talent, the Company is advancing its in-house R&D programs, and is also providing integrated research services to leading global pharmaceutical and biotechnology companies through Syngene and Clinigene. Biocon has rapidly developed a robust novel and biosimilars pipeline, focusing on Diabetes, Oncology and auto-immune diseases, which has several molecules at different stages of the development cycle. With the successful commercial launch of its first anti-cancer drug and several promising discovery partnerships in the clinic, the Company remains committed to scaling new heights in frontier science and achieving new milestones in affordable medicine

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Elanco Animal Health, Inc. engages in the innovation, development, manufacture and market products for companion and food animals. It offers products through the following four categories: Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein & Health, and Food Animal Ruminants & Swine. The Companion Animal Disease Prevention category engages in the broadest parasiticide portfolios in the companion animal sector based on indications, species and formulations, with products that protect pets from worms, fleas and ticks. The Companion Animal Therapeutics category provides the details of broad pain and osteoarthritis portfolio across species, modes of action, indications and disease stages. The Food Animal Future Protein & Health category includes vaccines, nutritional enzymes and animal-only antibiotics, serves the growing demand for protein and includes innovative products in poultry and aquaculture production, where demand for animal health products is outpacing overall industry growth. It also focuses on developing functional nutritional health products that promote food animal health, including enzymes, probiotics and prebiotics. The Food Animal Ruminants & Swine category develops animal food products used in ruminant and swine production. The company was founded on May 3, 2018 and is headquartered in Greenfield, IN.

Key Stats and Financials As of 2018
Market Capitalization
$7.47M
Total Enterprise Value
$-16.2M
Earnings Per Share
$-19.36
Revenue
$6.06M
Net Profit
$-66.5M
EBITDA
$-67.2M
EBITDAMargin
-1,108.64%
Total Debt
$0
Total Equity
$24.1M
Enterprise Value Sales
-2.67x
TEVNet Income
0.24x
Debt TEV
0x
Investors
Details Hidden

T. Rowe Price Group, Inc. is a financial services holding company, which engages in the provision of investment management services through its subsidiaries. It provides an array of company sponsored U.S. mutual funds, other sponsored pooled investment vehicles, sub advisory services, separate account management, recordkeeping, and related services to individuals, advisors, institutions, financial intermediaries, and retirement plan sponsors. The company was founded by Thomas Rowe Price Jr. in 1937 and is headquartered in Baltimore, MD.

Details Hidden

Sectoral is a fundamentals-based, medium- to long-term, GARP-oriented manager which focuses on companies in the healthcare (Pharmaceuticals, Generics, Biotechs and Medtechs) sector. They aim to achieve superior returns for investors by concentrating on primary research.The firm conducts preliminary research and analysis, including literature and documentation, interaction with companies and with Sectoral's Advisory Network, to identify investment candidates. They then conduct forecasting and scenario analyses, testing a range of assumptions and success factors critical to the company's success. They subsequently generate realistic valuation ranges for potential investments and assess the impact of the investment on the overall risk/return profile of the portfolio. They believe that specific risk is the most important risk component and have developed and refined their investment process to mitigate it.Their analysts attempt to determine the fair value for investment candidates as well as 1-year and 3-year price targets. Depending on the development stage of the company, they utilize models such as discounted cash-flow models, EBITDA models, classical growth models (PE approach), enterprise value/sales and peer group analysis to determine the price targets.Sectoral makes recommendations based on the resulting fair value to the current market value of each investment candidate and constructs portfolios comprised of analysts' investment recommendations. Their CIO determines the weight of each industry based on the attractiveness of expected growth, profitability, historic valuation and relative valuation.

Details Hidden

Cantor Fitzgerald is a leading global financial services firm at the forefront of financial and technological innovation. It is a preeminent capital markets investment bank serving more than 5,000 institutional clients around the world. Cantor Fitzgerald & Co. is one of 21 primary dealers authorized to trade U.S. government securities with The Federal Reserve Bank of New York. Cantor Fitzgerald's 1,600 employees serve clients through over 30 locations, including major financial centers around the world in the Americas, Europe, Asia/Pacific, and the Middle East.

Suppliers
University of Pennsylvania Investment Services & Portfolio Management | PHILADELPHIA, PA

The University of Pennsylvania (commonly referred to as Penn or UPenn) is a private, Ivy League university, located in Philadelphia, Pennsylvania, United States. Penn considers itself the fourth-oldest institution of higher education in the United States, as well as the first university in the United States with both undergraduate and graduate studies.

Competitors
Merck & Co., Inc. Pharmaceuticals - Kenilworth, NJ

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Seattle Genetics, Inc. Pharmaceuticals - Bothell, WA

Seattle Genetics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Its lead product, SGN-35, is in pivotal trial for patients with relapsed or refractory hodgkin lymphoma. The company's other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech; GlaxoSmithKline LLC; MedImmune, Inc.; Millennium; PSMA Development Company LLC; and Genmab A/S. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc. The company was founded in 1998 and is headquartered in Bothell, Washington.

Moderna, Inc. Biotechnology - Cambridge, Massachusetts

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Advaxis, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Advaxis, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Advaxis, Inc..